News | Heart Failure | July 05, 2016

New Electric Mesh Device Gives the Heart an Electromechanical Hug

Novel material closely mimics properties and functions of heart tissue, helps improve function in experimental models of heart failure

July 5, 2016 — A research team has developed a new electric mesh device that can be wrapped around the heart to deliver electrical impulses and improve cardiac function in experimental models of heart failure. The team was led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Seoul National University.

The study, published in the June 22 issue of Science Translational Medicine, points to a potential new way of improving heart function and treating dangerous arrhythmias by compensating for damaged cardiac muscle and enabling healthy heart muscle to work more efficiently.

Under normal conditions, the heart pumps blood throughout the body through a series of coordinated contractions maintained by a carefully synchronized electrical conduction system. With the development of heart failure — when weakened heart muscle damages the heart’s pumping mechanism — this electrical conduction system can be damaged.

“Some patients with heart failure are treated with resynchronization therapy, in which three pairs of small electrodes are implanted with a pacemaker to keep the heart contracting coordinately,” explained corresponding author Hye Jin Hwang, M.D., Ph.D., a researcher in the Division of Cardiovascular Medicine in BIDMC’s CardioVascular Institute. “But pacemakers deliver electrical stimulation only at specific places in the heart and do not provide comprehensive coverage of the entire organ, as the heart’s own cardiac electrical conduction system does.”

The research team, therefore, set out to develop an alternative device that would more closely resemble the human heart.

“In developing the novel material for this device, we wanted to closely imitate cardiac tissue, which is very elastic, and also imitate its unique functions, which is highly conductive,” said Hwang, who collaborated with Seoul National University researchers Taeghwan Hyeon, Ph.D., a specialist in nanomaterials, and Dae-Hyeong Kim, Ph.D., a specialist in stretchable devices, to create the new nanocomposite.

The result was a new mesh device made up of nanowires, wires thinner than human hair, embedded in a rubber polymer that can conform to the unique three-dimensional anatomy of each individual heart.

“The mesh essentially wraps around and ‘hugs’ the heart and delivers electrical impulses to the whole ventricular myocardium, or heart muscle, “ said Hwang.

Tests of the device in models of rats showed that the mesh was integrating both structurally and electrically with the myocardium following heart attack, acting as a substructure of the heart during cardiac movement and improving cardiac contractile function without disturbing relaxation. The next step, the authors said, will be to evaluate long-term performance of the novel electrical therapy with an upgraded device in large animal models, with the ultimate goal of clinical application in humans.

“We knew that an integrated strategic approach that prevents and suppresses irregular heartbeat in addition to improving cardiac function would be a promising strategy for the treatment of heart failure, ventricular arrhythmias and sudden death,” said coauthor Mark E. Josephson, M.D., chairman emeritus of cardiovascular medicine at BIDMC, Distinguished Herman Dana Professor of Medicine at Harvard Medical School, and an international leader in the field of electrophysiology.

“The big advance here has been finding a way to create a device that more accurately mimics normal physiology,” explained Peter J. Zimetbaum, M.D., associate chief and director of clinical cardiology at BIDMC and associate professor of medicine at Harvard Medical School. “The concept of wrapping the heart is not new, but doing it with this attention to a more physiologic approach makes the device exceptionally smart. This is not just another mechanical assist device. It’s an innovative physiologic approach and provides an opportunity to bridge sophisticated engineering and medicine.”

This work was supported by a grant from the Ministry of Science, ICT and Future Planning in Korea, as well as support from the National Science Foundation and the Institute of Computer Engineering and Sciences, University of Texas, Austin.

For more information: www.stm.sciencemag.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now